Placebo-only arm transcriptomic analysis of the phase 3 PROTECT clinical trial
收藏NIAID Data Ecosystem2026-03-13 收录
下载链接：
https://www.omicsdi.org/dataset/ega/EGAS00001006344
下载链接
链接失效反馈官方服务：
资源简介：
It is poorly understood how the tumor immune microenvironment influences disease recurrence in localized clear cell renal cell carcinoma (ccRCC). Here we perform whole-transcriptomic profiling of 236 tumors from patients assigned to the placebo-only arm of a randomized, adjuvant clinical trial for high-risk localized ccRCC. Unbiased pathway analysis identifies myeloid-derived interleukin-6 (IL-6) as a key mediator. Furthermore, a novel myeloid gene signature strongly correlates with disease recurrence and overall survival on uni- and multivariate analysis and is linked to TP53 inactivation across multiple datasets.EGA study EGAS00001006344
创建时间：
2022-07-05
